Skip to main content

Table 1 Demographic, clinical, and surgical characteristics of the patients

From: Perioperative allogenic blood transfusion increases the incidence of postoperative deep vein thrombosis in total knee and hip arthroplasty

Characteristics Total (n = 715) TKA (n = 319) THA (n = 396)
Gender
 Male (%) 208 (29.1) 58 (18.2) 150 (37.9)
 Female (%) 507 (70.9) 261 (81.8) 246 (62.1)
Age, years (mean ± SD) 65.1 ± 12.6 67.5 ± 9.2 63.2 ± 14.5
BMI, kg/m2 (mean ± SD) 24.7 ± 4.3 26.1 ± 4.1 23.5 ± 4.0
Diabetes (%) 116 (16.2) 69 (21.6) 47 (11.9)
Hypertension (%) 322 (45.0) 178 (55.8) 144 (36.4)
Malignance (%) 30 (4.2) 13 (4.1) 17 (4.3)
Cardiovascular disease (%) 84 (11.7) 40 (12.5) 44 (11.1)
Stroke (%) 95 (13.3) 48 (15.0) 47 (11.9)
COPD (%) 11 (1.5) 5 (1.6) 6 (1.5)
Venous disease (%) 24 (3.4) 16 (5.0) 8 (2.0)
Previous surgery (%) 18 (2.5) 1 (0.3) 17 (4.3)
Preoperative aspirin (%) 99 (13.8) 52 (16.3) 47 (11.9)
Preoperative steroid (%) 27 (3.8) 7 (2.2) 20 (5.1)
Smoking (%) 91 (12.7) 23 (7.2) 68 (17.2)
Diagnosis
 OA (%) 333 (46.6) 292 (91.5) 41 (10.4)
 RA (%) 36 (5.0) 27 (8.5) 9 (2.3)
 Femoral neck fracture (%) 133 (18.6) 133 (33.6)
 ONFH (%) 145 (20.3) 145 (36.6)
 DDH (%) 60 (8.4) 60 (15.2)
 AS (%) 8 (1.1) 8 (2.0)
Operation time, min (mean ± SD) 109.7 ± 29.0 119.4 ± 22.0 101.9 ± 31.4
Intraoperative blood loss, ml (mean ± SD) 258.8 ± 208.8 200.3 ± 136.3 306.0 ± 242.5
Chemical thromboprophylaxis
 None (%) 28 (3.9) 10 (3.1) 18 (4.5)
 Rivaroxaban (%) 599 (83.8) 279 (87.5) 320 (80.8)
 LMWH (%) 88 (12.3) 30 (9.4) 58 (14.6)
  1. aTKA total knee arthroplasty, THA total hip arthroplasty, SD standard deviation, BMI body mass index, COPD chronic obstructive pulmonary disease, OA osteoarthritis, RA rheumatoid arthritis, ONFH osteonecrosis of the femur head, DDH developmental dysplasia of the hip, AS ankylosing spondylitis, LMWH low-molecular-weight heparin